Back
Pfizer Inc. 10K Form
Sell
33
PFE
Pfizer Inc.
Last Price:
$25.16
Seasonality Move:
1.54%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2025-03-15 | 10K | PFE/Pfizer Inc. Annual |
| 2025-02-15 | 10K | PFE/Pfizer Inc. Annual |
| 2024-11-04 | 10Q | PFE/Pfizer Inc. Quarterly |
| 2024-08-05 | 10Q | PFE/Pfizer Inc. Quarterly |
| 2024-05-08 | 10Q | PFE/Pfizer Inc. Quarterly |
| 2024-02-22 | 10K | PFE/Pfizer Inc. Annual |
Receive PFE News And Ratings
See the #1 stock for the next 7 days that we like better than PFE
PFE Financial Statistics
Sales & Book Value
| Annual Sales: | $63.6B |
|---|---|
| Cash Flow: | $4B |
| Price / Cash Flow: | 13.86 |
| Annual Sales: | $16.32 |
| Price / Book: | 1.54 |
Profitability
| EPS (TTM): | 1.71560 |
|---|---|
| Net Income (TTM): | $9.8B |
| Gross Margin: | $41.8B |
| Return on Equity: | 10.84% |
| Return on Assets: | 4.66% |
Pfizer Inc. Earnings Forecast
Key Pfizer Inc. Financial Ratios
-
The Gross Profit Margin over the past 45 years for PFE is 65.77%.
-
The Selling, General & Administrative Expenses for PFE have been equal to 23.15% of Gross Profit Margin.
-
The Research & Development expenses have been 16.88% of Revenue.
-
The Interest Expense is 38.39% of Operating Income.
-
The Net Earning history of PFE is 12.65% of Total Revenues.
-
Per Share Earnings over the last 45 years have been positive in 24 years.
Pfizer Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | PFE |
| CUSIP: | 717081 |
| Website: | pfizer.com |
Debt
| Debt-to-Equity Ratio: | 0.67 |
|---|---|
| Current Ratio: | 1.28 |
| Quick Ratio: | 0.81 |
Price-to-Earnings
| Trailing P/E Ratio: | 17.9 |
|---|---|
| Forward P/E Ratio: | 8.36 |
PFE Technical Analysis vs Fundamental Analysis
Sell
33
Pfizer Inc. (PFE)
is a Sell
Is Pfizer Inc. a Buy or a Sell?
-
Pfizer Inc. stock is rated a SellThe current Pfizer Inc. [PFE] share price is $25.19. The Score for PFE is 33, which is 34% below its historic median score of 50, and infers higher risk than normal.